Australian & New Zealand Childrens Haematology/Oncology Group
Study Title
A Clinical and Molecular Risk-Directed Therapy For Newly Diagnosed Medulloblastoma
Protocol ID
SJMB12
Disease (Sub Disease)
Brain and Spinal Tumours (Medulloblastoma/PNET)
Diagnosis Stage
New diagnosis
Sponsor
St. Jude Children's Research Hospital
Collaborators
Genentech, Inc.
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Links
Trial Status
Closed to Recruitment
Study Type
Treatment
Phase
Phase 3
Age Eligibility
3 Years to 39 Years
International registry ID's
NCT01878617
| Study Title | A Clinical and Molecular Risk-Directed Therapy For Newly Diagnosed Medulloblastoma |
|---|---|
| Protocol ID | SJMB12 |
| Disease (Sub Disease) | Brain and Spinal Tumours (Medulloblastoma/PNET) |
| Diagnosis Stage | New diagnosis |
| Sponsor | St. Jude Children's Research Hospital |
| Collaborators | Genentech, Inc./ National Cancer Institute (NCI) |
| Links | https://clinicaltrials.gov/ct2/show/NCT01878617 |
| Trial Status | Closed to Recruitment |
| Trial Open Date | 12/03/2014 |
| Study Type | Treatment |
| Phase | Phase 3 |
| Age Eligibility | 3 Years to 39 Years |
| International registry ID's | NCT01878617 |